SAN FRANCISCO, July 10 /PRNewswire-FirstCall/ -- Osteologix Inc. today announced that Philip J. Young, President and CEO of Osteologix, will present a corporate overview Wednesday, July 11th at 8:00 a.m. during the C.E. Unterberg, Towbin (CEUT) Emerging Growth Opportunities Conference at the Mandarin Oriental Hotel in New York. A live audio webcast and slide presentation will be available via the internet by visiting http://www.wsw.com/webcast/ceut6/osteologix/.
About Osteologix and NB S101
Osteologix is developing NB S101, a once daily tablet containing strontium malonate, as a treatment for osteoporosis. The phase II study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial with the objective of assessing the effects of NB S101 on bone metabolism while also evaluating its safety, tolerability and pharmacokinetics in postmenopausal women. In addition to the primary endpoint of bone resorption, the company is evaluating the effects of NB S101 on bone formation and bone mineral density.
Osteologix Inc.CONTACT: Investors and Media, Baxter Phillips, III, Sr. Director,Corporate Development of Osteologix Inc., +1-804-747-6026,bp@osteologix.com
